Evidence on docosahexaenoic acid and arachidonic acid supplementation for preterm infants.
Journal
Current opinion in clinical nutrition and metabolic care
ISSN: 1473-6519
Titre abrégé: Curr Opin Clin Nutr Metab Care
Pays: England
ID NLM: 9804399
Informations de publication
Date de publication:
18 Mar 2024
18 Mar 2024
Historique:
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
aheadofprint
Résumé
For many decades, docosahexaenoic acid (DHA) supplementation was tested in premature infants to achieve an intake equivalent to the average level in breast milk, but this approach has led to conflicting results in terms of development and health outcomes. Higher doses of DHA closer to fetal accumulation may be needed. The efficacy of DHA supplementation for preterm infants at a dose equivalent to the estimated fetal accumulation rate is still under investigation, but this may be a promising approach, especially in conjunction with arachidonic acid supplementation. Current data suggest benefit for some outcomes, such as brain maturation, long-term cognitive function, and the prevention of retinopathy of prematurity. The possibility that supplementation with highly unsaturated oils increases the risk of neonatal morbidities should not be ruled out, but current meta-analyzes do not support a significant risk. The published literature supports a DHA intake in preterm infants that is closer to the fetal accumulation rate than the average breast milk content. Supplementation with DHA at this level in combination with arachidonic acid is currently being investigated and appears promising.
Identifiants
pubmed: 38547330
doi: 10.1097/MCO.0000000000001035
pii: 00075197-990000000-00147
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Dyall SC, Balas L, Bazan NG, et al. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: recent advances in the understanding of their biosynthesis, structures, and functions. Prog Lipid Res 2022; 86:101165.
Álvarez P, Ramiro-Cortijo D, Montes MT, et al. Randomized controlled trial of early arachidonic acid and docosahexaenoic acid enteral supplementation in very preterm infants. Front Pediatr 2022; 10:947221.
Zhang Z, Wang Y, Yang X, et al. Human milk lipid profiles around the world: a systematic review and meta-analysis. Adv Nutr 2022; 13:2519–2536.
Petersohn I, Hellinga AH, van Lee L, et al. Maternal diet and human milk composition: an updated systematic review. Front Nutr 2023; 10:1320560.
Liu W, Zeng T, Mueed A, et al. Dynamic changes at high-protein dietary pattern of major fatty acids in healthy lactating women: a systematic review and meta-analysis. Nutrition 2024; 121:112362.
Carnielli VP, Simonato M, Verlato G, et al. Synthesis of long-chain polyunsaturated fatty acids in preterm newborns fed formula with long-chain polyunsaturated fatty acids. Am J Clin Nutr 2007; 86:1323–1330.
Petermann AB, Reyna-Jeldes M, Ortega L, et al. Roles of the unsaturated fatty acid docosahexaenoic acid in the central nervous system: molecular and cellular insights. Int J Mol Sci 2022; 23:5390.
Lewandowski D, Sander CL, Tworak A, et al. Dynamic lipid turnover in photoreceptors and retinal pigment epithelium throughout life. Prog Retin Eye Res 2022; 89:101037.
Vizzari G, Morniroli D, Alessandretti F, et al. Comparative analysis of docosahexaenoic acid (DHA) content in mother's milk of term and preterm mothers. Nutrients 2022; 14:4595.
Giuffrida F, Fleith M, Goyer A, et al. Human milk fatty acid composition and its association with maternal blood and adipose tissue fatty acid content in a cohort of women from Europe. Eur J Nutr 2022; 61:2167–2182.
Niwa S, Kawabata T, Shoji K, et al. Investigation of maternal diet and FADS1 polymorphism associated with long-chain polyunsaturated fatty acid compositions in human milk. Nutrients 2022; 14:2160.
Kasamatsu A, Tachimoto H, Urashima M. Impact of maternal fish consumption on serum docosahexaenoic acid (DHA) levels in breastfed infants: a Cross-sectional study of a randomized clinical trial in Japan. Nutrients 2023; 15:4338.
Sjöbom U, Andersson MX, Pivodic A, et al. Modification of serum fatty acids in preterm infants by parenteral lipids and enteral docosahexaenoic acid/arachidonic acid: a secondary analysis of the Mega Donna Mega trial. Clin Nutr 2023; 42:962–971.
Gillespie TC, Kim ES, Grogan T, et al. Decreased levels of erythrocyte membrane arachidonic and docosahexaenoic acids are associated with retinopathy of prematurity. Invest Ophthalmol Vis Sci 2022; 63:23.
Castillo Salinas F, Montaner Ramón A, Castillo Ferrer F-J, et al. Erythrocyte membrane docosahexaenoic acid (DHA) and lipid profile in preterm infants at Birth and Over the first month of life: a comparative study with infants at term. Nutrients 2022; 14:4956.
Sinclair AJ, Wang Y, Li D. What is the evidence for dietary-induced DHA deficiency in human brains? Nutrients 2022; 15:161.
Lapillonne A, Eleni dit Trolli S, Kermorvant-Duchemin E. Postnatal docosahexaenoic acid deficiency is an inevitable consequence of current recommendations and practice in preterm infants. Neonatology 2010; 98:397–403.
Sambra V, Echeverria F, Valenzuela A, et al. Docosahexaenoic and arachidonic acids as neuroprotective nutrients throughout the life cycle. Nutrients 2021; 13:986.
Brenna JT. Animal studies of the functional consequences of suboptimal polyunsaturated fatty acid status during pregnancy, lactation and early postnatal life. Matern Child Nutr 2011; 7: (Suppl 2): 59–79.
McCann JC, Ames BN. Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 2005; 82:281–295.
Fu Z, Yan W, Chen CT, et al. Omega-3/Omega-6 long-chain fatty acid imbalance in Phase I retinopathy of prematurity. Nutrients 2022; 14:1333.
Shulkin M, Pimpin L, Bellinger D, et al. n-3 fatty acid supplementation in mothers, preterm infants, and term infants and childhood psychomotor and visual development: a systematic review and meta-analysis. J Nutr 2018; 148:409–418.
Makrides M, Gibson RA, McPhee AJ, et al. Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. JAMA 2009; 301:175–182.
Smithers LG, Gibson RA, McPhee A, et al. Higher dose of docosahexaenoic acid in the neonatal period improves visual acuity of preterm infants: results of a randomized controlled trial. Am J Clin Nutr 2008; 88:1049–1056.
Smithers LG, Collins CT, Simmonds LA, et al. Feeding preterm infants milk with a higher dose of docosahexaenoic acid than that used in current practice does not influence language or behavior in early childhood: a follow-up study of a randomized controlled trial. Am J Clin Nutr 2010; 91:628–634.
Collins CT, Makrides M, Gibson RA, et al. Pre and postterm growth in preterm infants supplemented with higher-dose DHA: a randomised controlled trial. Br J Nutr 2011; 105:1635–1643.
Manley BJ, Makrides M, Collins CT, et al. High-dose docosahexaenoic acid supplementation of preterm infants: respiratory and allergy outcomes. Pediatrics 2011; 128:e71–e77.
Atwell K, Collins CT, Sullivan TR, et al. Respiratory hospitalisation of infants supplemented with docosahexaenoic acid as preterm neonates. J Paediatr Child Health 2013; 49:E17–E22.
Jasani B, Simmer K, Patole SK, et al. Long chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 2017; 3:CD000376.
Best KP, Sullivan TR, Gunaratne AW, et al. Effect of docosahexaenoic acid (DHA) supplementation of preterm infants on growth, body composition, and blood pressure at 7-years corrected age: follow-up of a randomized controlled trial. Nutrients 2023; 15:335.
Gould JF, Bednarz JM, Sullivan TR, et al. Subgroup analyses of a randomized trial of DHA supplementation for infants born preterm with assessments of cognitive development up to 7-years of age: what happens in infants born <29 weeks’ gestation? Prostaglandins Leukot Essent Fatty Acids 2023; 198-199:102593.
Marc I, Piedboeuf B, Lacaze-Masmonteil T, et al. Effect of maternal docosahexaenoic acid supplementation on bronchopulmonary dysplasia-free survival in breastfed preterm infants: a randomized clinical trial. JAMA 2020; 324:157–167.
Guillot M, Synnes A, Pronovost E, et al. Maternal high-dose DHA supplementation and neurodevelopment at 18-22 months of preterm children. Pediatrics 2022; 150:e2021055819.
Collins CT, Makrides M, McPhee AJ, et al. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants. N Engl J Med 2017; 376:1245–1255.
Hewawasam E, Collins CT, Muhlhausler BS, et al. DHA supplementation in infants born preterm and the effect on attention at 18 months’ corrected age: follow-up of a subset of the N3RO randomised controlled trial. Br J Nutr 2021; 125:420–431.
Gould JF, Makrides M, Gibson RA, et al. Neonatal docosahexaenoic acid in preterm infants and intelligence at 5 years. N Engl J Med 2022; 387:1579–1588.
Gould JF, Roberts RM, Anderson PJ, et al. High-dose docosahexaenoic acid in newborns born at less than 29 weeks’ gestation and behavior at age 5 years: follow-up of a randomized clinical trial. JAMA Pediatr 2024; 178:45–54.
Sullivan TR, Gould JF, Bednarz JM, et al. Mediation analysis to untangle opposing associations of high-dose docosahexaenoic acid with IQ and bronchopulmonary dysplasia in children born preterm. JAMA Netw Open 2023; 6:e2317870.
Koletzko B, Bergmann K, Brenna JT, et al. Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation. Am J Clin Nutr 2020; 111:10–16.
Colombo J, Jill Shaddy D, Kerling EH, et al. Docosahexaenoic acid (DHA) and arachidonic acid (ARA) balance in developmental outcomes. Prostaglandins Leukot Essent Fatty Acids 2017; 121:52–56.
Alshweki A, Munuzuri AP, Bana AM, et al. Effects of different arachidonic acid supplementation on psychomotor development in very preterm infants; a randomized controlled trial. Nutr J 2015; 14:101.
Hellström A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 2021; 175:359–367.
Hellström A, Pivodic A, Gränse L, et al. Association of docosahexaenoic acid and arachidonic acid serum levels with retinopathy of prematurity in preterm infants. JAMA Netw Open 2021; 4:e2128771.
Diggikar S, Aradhya AS, Swamy RS, et al. Effect of enteral long-chain polyunsaturated fatty acids on retinopathy of prematurity: a systematic review and meta-analysis. Neonatology 2022; 119:547–557.
Lundgren P, Jacobson L, Gränse L, et al. Visual outcome at 2.5 years of age in ω-3 and ω-6 long-chain polyunsaturated fatty acid supplemented preterm infants: a follow-up of a randomized controlled trial. Lancet Reg Health Eur 2023; 32:100696.
Wackernagel D, Nilsson A, Sjobom U, et al. Enteral supplementation with arachidonic and docosahexaenoic acid and pulmonary outcome in extremely preterm infants. Prostaglandins Leukot Essent Fatty Acids 2024; 201:102613.
Wendel K, Pfeiffer HCV, Fugelseth DM, et al. Effects of nutrition therapy on growth, inflammation and metabolism in immature infants: a study protocol of a double-blind randomized controlled trial (ImNuT). BMC Pediatr 2021; 21:19.
Wendel K, Aas MF, Gunnarsdottir G, et al. Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants. Clin Nutr 2023; 42:22–28.
Wendel K, Gunnarsdottir G, Fossan Aas M, et al. Essential fatty acid supplementation and early inflammation in preterm infants: secondary analysis of a randomized clinical trial. Neonatology 2023; 120:465–472.
Wendel K, Rossholt ME, Gunnarsdottir G, et al. Lung function in preterm infants at 3 months corrected age after neonatal LC-PUFA supplementation. Pediatr Pulmonol 2024; 59:389–398.
Rossholt ME, Bratlie M, Wendel K, et al. Effect of arachidonic and docosahexaenoic acid supplementation on quality of growth in preterm infants: a secondary analysis of a randomized controlled trial. Clin Nutr 2023; 42:2311–2319.
Moltu SJ, Nordvik T, Rossholt ME, et al. Arachidonic and docosahexaenoic acid supplementation and brain maturation in preterm infants; a double blind RCT. Clin Nutr 2024; 43:176–186.
Tanaka K, Tanaka S, Shah N, et al. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2020; 35:1730–1738.
Marc I, Boutin A, Pronovost E, et al. Association between enteral supplementation with high-dose docosahexaenoic acid and risk of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis. JAMA Netw Open 2023; 6:e233934.
Embleton ND, Moltu SJ, Lapillonne A, et al. Enteral nutrition in preterm infants (2022): a Position Paper from the ESPGHAN Committee on Nutrition and Invited Experts. J Pediatr Gastroenterol Nutr 2023; 76:248–268.
Plourde M, Chouinard-Watkins R, Vandal M, et al. Plasma incorporation, apparent retroconversion and β-oxidation of 13C-docosahexaenoic acid in the elderly. Nutr Metab (Lond) 2011; 8:5.